Related references
Note: Only part of the references are listed.Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
Tomoyuki Tanaka et al.
SCIENTIFIC REPORTS (2021)
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology
Congcong Zhang et al.
BIODRUGS (2020)
HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
Tianshu Xiao et al.
NATURE CHEMICAL BIOLOGY (2020)
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Nicolas Bery et al.
NATURE COMMUNICATIONS (2020)
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
Nicolas Bery et al.
NATURE COMMUNICATIONS (2019)
Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3
Jennifer S. Chambers et al.
SCIENTIFIC REPORTS (2019)
Facile target validation in an animal model with intracellularly expressed monobodies
Ankit Gupta et al.
NATURE CHEMICAL BIOLOGY (2018)
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Camilo E. Quevedo et al.
NATURE COMMUNICATIONS (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
Inhibition of RAS function through targeting an allosteric regulatory site
Russell Spencer-Smith et al.
NATURE CHEMICAL BIOLOGY (2017)
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors
Vassilios Bavetsias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge
Duncan E. Scott et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Photoaffinity labeling in target- and binding-site identification
Ewan Smith et al.
FUTURE MEDICINAL CHEMISTRY (2015)
LMO2 at 25 years: a paradigm of chromosomal translocation proteins
Jennifer Chambers et al.
OPEN BIOLOGY (2015)
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Michelle R. Arkin et al.
CHEMISTRY & BIOLOGY (2014)
Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody
Mi Young Koo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex
H. Sewell et al.
SCIENTIFIC REPORTS (2014)
Protein-protein interactions as druggable targets: recent technological advances
Alicia P. Higueruelo et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization
Hugo Lavoie et al.
NATURE CHEMICAL BIOLOGY (2013)
Conformation-Sensing Antibodies Stabilize the Oxidized Form of PTP1B and Inhibit Its Phosphatase Activity
Aftabul Haque et al.
CELL (2011)
Single Domain Intracellular Antibodies from Diverse Libraries EMPHASIZING DUAL FUNCTIONS OF LMO2 PROTEIN INTERACTIONS USING A SINGLE VH DOMAIN
Tomoyuki Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Intracellular antibodies and cancer: New technologies offer therapeutic opportunities
David Perez-Martinez et al.
BIOESSAYS (2010)
PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces
Salam A. Assi et al.
NUCLEIC ACIDS RESEARCH (2010)
Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth
T. Tanaka et al.
ONCOGENE (2010)
Commonality but Diversity in Cancer Gene Fusions
Terence H. Rabbitts
CELL (2009)
Interfering with protein-protein interactions - Potential for cancer therapy
Tomoyuki Tanaka et al.
CELL CYCLE (2008)
An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions
C-H Nam et al.
ONCOGENE (2008)
A protein silencing switch by ligand-induced proteasome-targeting intrabodies
Teresa Melchionna et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS
Tomoyuki Tanaka et al.
EMBO JOURNAL (2007)
Identification of the key LMO2-binding determinants on Ldb1
Daniel P. Ryan et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Photochemical fishing approaches for identifying target proteins and elucidating the structure of a ligand-binding region using carbene-generating photoreactive probes
Y Sadakane et al.
ANALYTICAL SCIENCES (2006)
Gene expression profiling in T-cell acute lymphoblastic leukemia
AA Ferrando et al.
SEMINARS IN HEMATOLOGY (2003)
Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation
T Tanaka et al.
EMBO JOURNAL (2003)
The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development
MP McCormack et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Intracellular antibody-caspase-mediated cell killing: An approach for application in cancer therapy
E Tse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
